PB2148: EFFICACY OF SMALL MOLECULE TARGET THERAPIES IN REFRACTORY OR RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA AND MOLECULAR SUBTYPING: A MULTI-CENTER REAL-WORLD EVIDENCE

PB2148: EFFICACY OF SMALL MOLECULE TARGET THERAPIES IN REFRACTORY OR RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA AND MOLECULAR SUBTYPING: A MULTI-CENTER REAL-WORLD EVIDENCE

Bibliographic Details
Main Authors:	Y. Zhang, Y. Hou, X. Zhou, L. Sun, W. Wang, Y. Wo, Y. Sun, Q. Xu, P. Liu
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000851420.29393.a1

Similar Items

PB2095: RELAPSED AND REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: EXPERIENCE OF A LOW-INCOME CENTER IN TIME OF NEW DRUGS
by: M. Charfi, et al.
Published: (2022-06-01)

PB2064: RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS TREATED WITH RADIOTHERAPY
by: F. Kallel, et al.
Published: (2022-06-01)

PB2063: CHARACTERISTICS AND THERAPEUTIC RESULTS OF PATIENTS WITH REFRACTORY/RELAPSED HODGKIN LYMPHOMA IN A TUNISIAN CENTER
by: F. Kammoun, et al.
Published: (2022-06-01)

PB2262: PROGNOSTIC FACTORS IN PATIENTS WITH RELAPSED/REFRACTORY HODGKINN LYMPHOMA
by: Kmira Zahra, et al.
Published: (2023-08-01)

The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma
by: Tingxun Lu, et al.
Published: (2023-08-01)

Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
by: Leonard Jeff Harris, et al.
Published: (2020-11-01)

Relapsed/Refractory Hodgkin Lymphoma
by: Semira Sheikh, et al.
Published: (2018-06-01)

PB2148: IMPACT OF OBESITY IN THE CLINICAL OF MULTIPLE MYELOMA PATIENTS: A REPORT FROM MMRF DATASET
by: Liang Ren, et al.
Published: (2023-08-01)

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma
by: Xiaoshuang Kong, et al.
Published: (2023-04-01)

Nivolumab in relapsed/refractory Hodgkin Lymphoma patients, single center experiences
by: Ramazan Acar, et al.
Published: (2020-12-01)

PB2072: EFFICACY AND SIDE EFFECTS OF IBRUTINIB IN RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA
by: A. Basturk, et al.
Published: (2022-06-01)

Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
by: Eva Gonzalez Barca
Published: (2023-11-01)

Single-Center Retrospective Clinical Evaluation of Venetoclax Combined with HMAs and Half-Dose CAG for Unfit or Refractory/Relapsed AML
by: Chen X, et al.
Published: (2023-06-01)

Blinatumomab in Relapsed/Refractory Burkitt Lymphoma
by: Jeanne Bohler, et al.
Published: (2022-12-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

2148 Understanding the health effects of binding and tucking for gender affirmation
by: Tonia Poteat, et al.
Published: (2018-06-01)

PB2263: TOXICITY PROFILE OF SALVAGE CHEMOTHERAPY REGIMENS IN PATIENTS WITH RELAPSED/ REFRACTORY HODGKIN LYMPHOMA.
by: Kmira Zahra, et al.
Published: (2023-08-01)

Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options
by: Alejandro Martín García-Sancho, et al.
Published: (2023-12-01)

New Frontiers in Monoclonal Antibodies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
by: Mattia Schipani, et al.
Published: (2023-12-01)

Elucidating Targetable Genetic Vulnerabilities in Relapsed/Refractory Diffuse Large B-cell Lymphoma
by: Li, Audrey
Published: (2024)

Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
by: Xianggui Yuan, et al.
Published: (2022-11-01)

PB2254: TREATMENT OUTCOME AND PROGNOSTIC FACTORS IN CHILDREN AND ADOLESCENTS WITH RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
by: Nesreen Ali, et al.
Published: (2023-08-01)

PB2297: PHASE II STUDY OF BORTEZOMIB, CYTARABINE, AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA
by: Junghoon Shin, et al.
Published: (2023-08-01)

Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Look at the Approved and Emerging Therapies
by: Yazeed Sawalha
Published: (2021-12-01)

Systematic review of outcomes and patient heterogeneity in relapsed or refractory diffuse large B-cell lymphoma
by: Sally D Miller, et al.
Published: (2022-11-01)

Pretreatment diffusion-weighted imaging for prediction of relapsed and refractory primary central nervous system lymphoma
by: Hsi-Cheng Chien, et al.
Published: (2023-08-01)

Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era
by: Eva González Barca
Published: (2022-07-01)

P1096: TREATMENT PATTERNS AND OUTCOMES IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
by: A. Bock, et al.
Published: (2022-06-01)

PB2339: CLINICAL OUTCOMES OF RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: THE ROLE OF AUTOLOGOUS STEM-CELL TRANSPLANTATION IN AN INTEND TO TREAT POPULATION
by: Isabel Paulos Mesquita, et al.
Published: (2023-08-01)

PB2311: EFFICACY EVALUATION AND SAFETY ANALYSIS OF ZANUBRUTINI B COMBINED WITH CHEMOTHERAPY FOR 17 CASES OF RELAPSED REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
by: Qingfeng Chen, et al.
Published: (2023-08-01)

PB2144: PEARL: A STUDY TO ASSESS THE EFFICACY AND SAFETY OF PENPULIMAB PLUS LENALIDOMIDE, RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
by: X. Wei, et al.
Published: (2022-06-01)

PB2357: TRIAL IN PROGRESS: OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH SYSTEMIC THERAPY FROM REAL-WORLD EXPERIENCE (ORCHID)
by: Catherine Thieblemont, et al.
Published: (2023-08-01)

P378: THE PROGNOSIS FACTORS OF CAR-T THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY B-ALL
by: Y. Wang, et al.
Published: (2022-06-01)

PB2143: CLINICAL CHARACTERISTICS AND PROGNOSTIC FEATURES OF 63 HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE-CENTER REAL-WORLD STUDY IN CHINA
by: C. Wang, et al.
Published: (2022-06-01)

Advances in the treatment of relapsed/refractory marginal zone lymphoma
by: Haotian Wang, et al.
Published: (2024-01-01)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
by: Timothy J Voorhees, et al.
Published: (2020-10-01)

Therapeutic Advances in Relapsed and Refractory Peripheral T-Cell Lymphoma
by: Robert Stuver, et al.
Published: (2023-01-01)

Treatment selection for patients with relapsed or refractory follicular lymphoma
by: Alan Z. Skarbnik, et al.
Published: (2023-03-01)

Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma
by: S Galimberti, et al.
Published: (2010-06-01)

PB2259: THE NEW PD-1 INHIBITOR PROLGOLIMAB IN THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN’S LYMPHOMA
by: Anastasia Semenova, et al.
Published: (2023-08-01)